Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eltrombopag Olamine in Healthy Fasting Subjects
NCT06768632Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eltrombopag in Thrombocytopenia (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Concentration at 72 hours, Time to maximum concentration at 72 hours and 6 more. Started Jan 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06768632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768632.